A randomized, double-blind, double-dummy, placebo-controlled, parallel-group study to assess & compare efficacy & safety of an 8-week treatment with Respimat® inhaler & fluticasone propionate in patients with asthma inadequately controlled on ICS therapy
Description of Research
The aim of this clinical study is to compare the efficacy and safety of three different doses of BI 54903 administered via Respimat inhaler with fluticasone and placebo (a compound that is identical in appearance but does not contain any active ingredient).
Participants suffer from asthma. Patients with asthma may take part in this study if they are being treated with medium to high doses of an inhaled corticosteroid.